Veranova Breaks Ground on ADC Facility Expansion

Government officials, industry leaders, and local business representatives gathered to mark the groundbreaking of Veranova’s latest expansion at its Devens, MA facility. Image: Courtesy of Veranova

Global CDMO Veranova recently celebrated the groundbreaking of its latest expansion at its Devens, MA facility. The groundbreaking ceremony, held on June 18, 2025, brought together government officials, industry leaders, and local business representatives to celebrate this strategic investment.

First announced in June 2024, the expansion demonstrates Veranova’s continued investment in advanced infrastructure to meet the growing demand for high-potency and controlled substance API manufacturing. The project also underscores the company’s support for strengthening US pharmaceutical supply chains amid a challenging global landscape. By strengthening supply chains and supporting global pharma needs, Veranova moves closer to its mission of becoming the go-to partner for the next wave of cutting-edge therapeutics.

Building upon Veranova’s already advanced range of services in Devens, the expansion will add 9,000 square feet to the site, including a new state-of-the-art process development laboratory and two current Good Manufacturing Practice (cGMP) suites. These new capabilities will expand the site’s development and production capabilities for ADCs and other potent small molecules for the treatment of cancer, rare diseases and other indications.

Attending the event was US Congresswoman Lori Trahan (MA-03), who highlighted the vital role of local job creation in driving global competitiveness in advanced pharmaceutical manufacturing: “The fight to end cancer once and for all depends on trailblazers like Veranova, where innovative work in specialty medications is reshaping treatment options for cancer and rare diseases. Their new facility in Devens will create good-paying jobs, boost economic growth, and bolster the domestic supply of active medical ingredients—ensuring Massachusetts stays at the forefront of health care innovation.”

Previous to the Groundbreaking Ceremony, Veranova announced a complementary scheme to establish state-of-the-art bioconjugation development and cGMP manufacturing capabilities at the Devens site. Combined, these initiatives represent a more than $50 million investment. Veranova CEO Mike Riley expects them to strengthen US-based infrastructure for ADCs and bioconjugates and create up to 70 new jobs.

Mike Riley, CEO of Veranova, highlighted the expansion as a strategic investment in innovation and domestic manufacturing capacity. “This expansion reflects Veranova’s deep commitment to supporting our partners in the development and manufacture of complex, life-saving therapies. By enhancing our capabilities in Devens, we’re not only investing in innovation and growth, but also strengthening domestic infrastructure for the production of critical medicines like ADCs and other highly potent compounds.”